Weekly Evidence Report

Health Technology Assessment Philippines

12-8 DECEMBER 2020

Overview

The following report presents summaries of evidence the Department of Health (DOH) - Health Technology Assessment (HTA) Unit reviewed for the period of 12 to 18 December 2020. The HTA Unit reviewed a total of 16 studies for the said period.

Evidence includes 1 study on Epidemiology; 1 studies on Transmission;1 study on Drugs; 7 studies on Vaccines, 0 studies on Equipment and Devices; 1 study on Medical and Surgical Procedures; 0 studies on Traditional Medicine; and 5 studies on Preventive & Promotive Health.

The following report notes that 3 studies have not been peer-reviewed, each highlighted accordingly.

Included the link to the HTA Living Database on COVID-19 Vaccines

Sections

Epidemiology	
Transmission	
Drugs	
Vaccines	
Equipment & Devices	
Medical & Surgical Procedures	
Traditional Medicine	
Preventive & Promotive Health	





Evidence on Epidemiology

Local COVID-19 Tracker: <u>https://www.doh.gov.ph/covid19tracker</u> Local COVID-19 Case Tracker: <u>https://www.doh.gov.ph/covid-19/case-tracker</u>

Date	Author/s	Title	Journal/ Article Type	Summary
14 Dec 2020	ASEAN Biodiaspora Virtual Center	Risk Assessment for International Dissemination of COVID-19 to the ASEAN Region	ABVC (Risk Assessment)	 Globally, 72.4 million and 1.6 million cases and deaths from COVID-19 have been reported respectively Indonesia, being the most populous in the region, has seen a gradual increase in cases now with a reported 617,820 cases and a death toll of 18,819 The Philippines shows to have the second highest with a still increasing number totalling to 449,400 cases The Singapore-Hong Kong travel bubble has been turned to include a 14 day quarantine period and RT-PCR testing 72 hours before departure Malaysia, on the other hand, has reduced quarantine for incoming travellers to 10 days from 2 weeks based on the latest evidences

Evidence on Vulnerable Population Epidemiology

Date	Author/s	Title	Journal/ Article Type	Summary
				•

Evidence on Transmission

Date	Author/s	Title	Journal/ Article Type	Summary
16 Dec 2020	Kalantari, et.al.	The association of COVID-19 Infection with Household food insecurity among Iranian population	MedRxiv (Cross-sectional study)	 The study aimed to find the association of food security score with the status of COVID-19 infection 2,871 adults were included in the study Food insecurity score is higher among those infected with COVID-19 [OR=1.03, CI 1.00-1.05, p < 0.05)

Evidence on Drugs

Date	Author/s	Title	Journal/ Article Type	Summary
16 Dec 2020	Ravichandran et.al.	Efficacy and Safety of Indomethacin in COVID-19 patients	MedRxiv (Experimental Study)	 Two centers were included in the study where patients who tested positive for COVID-19 were included One out of 72 patients of the first group of participants needed supplemental oxygen while for the comparator group, 28 out of 72 needed supplemental oxygen It was concluded that Indomethacin with standard of care can provide symptomatic relief and could prevent progression of disease

Evidence on Vaccines

Link to HTA Living Database: <u>https://bit.ly/3gOOSmG</u>

NYT Coronavirus Vaccine Tracker:

https://www.nytimes.com/interactive/2020/science/coronavirus-vaccine-tracker.html

Bloomberg Vaccine Tracker: https://www.bloomberg.com/graphics/covid-vaccine-tracker-global-distribution/

London School of Hygiene and Tropical Medicine Vaccine Trial Mapper and Tracker: <u>https://vac-lshtm.shinyapps.io/ncov_vaccine_landscape/</u>

ACIP Files:

https://drive.google.com/drive/u/0/folders/1v-jd66qllxnUkfzXWKqiD0mkVvqy VvJ

Date	Author/s	Title	Journal/ Article Type	Summary
14 Dec 2020	Sim, D.	Singapore to get Pfizer-BioNTech vaccine by end of December; plans to vaccinate all on free but voluntary basis by Q3, 2021	South China Morning Post (News Article)	 Prime Minister Lee Hsien Loong announced that the country would be offering free and voluntary vaccination to the entire population before the second half of 2021 The first batch of Pfizer-BioNTech vaccines will be received by the end of December
11 Dec 2020	Australia MoH	<u>Australia secures 20</u> <u>million extra Astra</u> <u>Zeneca vaccines</u>	Australia MoH (Media Release)	 The additional 20 million vaccines acquired adds up to the total population with 53.8 million Astra Zeneca doses for 2021 with the 20 million additional vaccines being produced locally by CSL Other purchases include 11 added million from Novovax and the scheduled 10 million doses of Pfizer/BioNTech for early 2021 The University of Queensland's clinical trials will not continue to phase three after finishing its first phase trial
10 Dec 2020	Polack, et.al.	Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine	NEJM (Clinical Trial)	• A two-dose regimen of Pfizer/BioNTech vaccine conferred a 95% immunity against COVID-19 for people aged 16 years and above

Date	Author/s	Title	Journal/ Article Type	Summary
16 Dec 2020	UK MHRA	Fifth COVID-19 vaccine starts UK clinical trials	UK MHRA (Press Release)	 60 million units have been pre-ordered of the Livinston, West Lothian developed vaccine Valneva will be given initially to four National Institute for Health Research facilities to 150 individuals The Livingston facility is set to be expanded as a governmental investment to be able to provide a projected 250 million vaccine doses Valneva joins Oxford/AstraZeneca, Imperial College London, Novovax and Janssen as ongoing clinical trials
8 Dec 2020	Voysey, et.al.	Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD12222) against SARS CoV-2: an interim analysis of four randomised controlled trials in Brazil. South Africa, and the UK	Lancet (Randomised control trial)	 11,363 participants were included distributed between those given the standard dose and low dose. Overall vaccine efficacy for both groups was 70.4% (95.8% CI, 54.8 to 80.6; 30 [0.5%] of 5807 vs 101 [1.7%] of 5829) Astrazeneca was seen to be efficacious versus symptomatic COVID-19
15 Dec 2020	Raches, et.al.	Safety and immunogenicity trial of an inactivated SARS-CoV-2 vaccine-BBV152: a phase I, double-blind, randomised control trial	MedRxiv (Randomised control trial)	 375 participants were included in the study under Bharat Biotech being given three vaccine formulations All three vaccine formulations produced immune responses where no significant difference was seen between 3 micgrogram and 6 microgram No retrogenicity was noted and most of adverse events are mild and easily resolved

Advisory Committee on Immunization Practices (ACIP) Updates

Date	Author/s	Title	Journal/ Article Type	Summary
11-12 Dec	Bell, et.al.	December 11-12. 2020 ACIP Meeting	Meeting presentations	 ACIP discussed Safety and Efficacy Data; discussed GRADE
2020		Video Recordings		evaluation and EtR Framework of the Pfizer-BioNTech vaccine.

Date	Author/s	Title	Journal/ Article Type	Summary
17 Dec 2020	US FDA	Vaccines and Related Biological Products Advisory Committee December 17, 2020 Meeting Announcement	US FDA (Meeting Announcement)	• With a 20 to 1 yes to abstain ratio, Moderna has been granted the Emergency Use Authorization by US FDA

Evidence on Equipment & Devices

Date	Author/s	Title	Journal/ Article Type	Summary
				•

Evidence on Medical & Surgical Procedures

Date	Author/s	Title	Journal/ Article Type	Summary
23 Mar 2020 Updated 10 Dec 2020	ECDC	Coronavirus disease 2019 (COVID-19) and supply of substances of human origin in the EU/EEA-second update	ECDC (Guidance Document)	 Updates included in the document discusses classification of areas for regulating the movement of population, reassessment of COVID-19 risk, impact of COVID-19 on SoHo supply, and other matters such as mitigation measures ECDC publishes a weekly epidemiologic update by region. Currently, no record in EU was done showing COVID-19 transmission via SoHo. Mitigation measures are suggested to be continued to prevent a possibility of a COVID-19 transmission via SoHo Temporary deferral for 2 weeks from procedures for donors is a body temperature of 37.5C. Donors must be deferred four weeks after receiving vaccination with attenuated viruses

Evidence on Traditional Medicine

Date	Author/s	Title	Journal/ Article Type	Summary
				•

Evidence on Preventive & Promotive Health

Evidence on Screening

Date	Author/s	Title	Journal/ Article Type	Summary
2 Oct 2020 Updated 14 Dec 2020	Public Health England	COVID-19: Investigation and initial clinical management of possible cases	PHE (Guidance Document)	• The latest update on the guidance for screening of possible cases include the change of self-isolation of 10 days instead of 14 days
10 Dec 2020	HSE	Summary of Evidence for waste water surveillance to enhance other forms of surveillance for COVID-19	HSE	 Screening of wastewater has been seen by studies to reveal possible outbreaks in the early stages UK and the Netherlands have started wastewater surveillance with the WHO noting that the practice may complement public health data

Evidence on Personal Measures

Date	Author/s	Title	Journal/ Article Type	Summary
Updated 14 Dec 2020	Public Health England	Stay at home: guidance for households with possible or confirmed coronavirus (COVID-19) infection	Public Health England (Guidance Document)	 The update reduced the originally 14 day self-isolation period to 10 days if there be any symptoms that manifest within the household The isolation period includes the day symptoms started and the next 10 full days

 PCR tests or LFD tests are still the tests allowed for this purpose

Evidence on Community Measures

Date	Author/s	Title	Journal/ Article Type	Summary
13 Dec 2020	Malaysia MoH	Pengurusan Kuarantin Pengembara dari luar negara dan kontak rapat di Malaysia	Malaysian MoH (Article)	 (Translated using Google Translate) The country has reduced quarantine for travelers returning from abroad and those with close contact from 14 days to 10 days They have done so in line with the reduced days in other countries such as UK, Germany and Belgium with 10 days and France with 7 days The concept is in the fact that clinical evidence showed the risk of post-quarantine infection will decrease over a period of quarantine time with a week after exposure being the peak of the rate of infection
12 Dec 2020	Ministere des Solidarites et de la Sante Translated by Google Translate	(Protecting seniors without isolating them: Relaxation of recommendations for EHPAD for the end of year celebrations)	Ministere des Solidarites et de la Sante (Press Release)	 Recommendations are set for the holidays implemented from 15 December 2020 to 3 January 2021 RT-PCR tests are encouraged for elderly in facilities visiting family for the holidays when they return to the institution 7 days hold on group activities are to be done Visitors in homes are suggested to be reduced to a number per resident